.svg){kind=logo}
.svg){kind=icon}
MENU
CLOSE
MENU
CLOSE
We are collaborating on clinical trials for a new treatment for this sometimes fatal common infection
Strongyloidiasis is a soil-transmitted helminth infection caused by strongyloides stercoralis. The WHO estimates that up to 100 million people, particularly children, are infected with this parasitic worm. The causative worm has a different lifecycle from other soil-transmitted helminths and infection can be fatal.
≈100M
people, particularly children, are infected
0
public health strategies for controlling this disease are active at the global level
Source:
World Health Organization. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases.
World Health Organization. WHO Strongyloidiasis fact sheet.
-
Children are particularly vulnerable to this infection
Treatment options are limited, with ivermectin, an anti-parasitic, being the medicine of choice, while other anthelmintic medicines such as albendazole and mebendazole, which limit the parasite’s absorption of sugar, lack sufficient efficacy as a single dose.
MDGH is collaborating in clinical trials of moxidectin as a treatment for strongyloidiasis in Cambodia and Laos led by the Swiss Tropical and Public Health Institute, Switzerland.
A paediatric dose-finding study, a phase 3b trial comparing efficacy and safety of annual and biannual moxidectin or ivermectin treatment and mathematical modelling of moxidectin and ivermectin based elimination strategies to support country policy decisions.
Primarily affecting the lungs, tuberculosis remains the leading cause of infectious death worldwide.
A debilitating and disfiguring disease found in 31 African countries and beyond.
An infectious skin condition affecting more than 200 million people at any one time.
A painful and debilitating disease of the lymph system affecting over 50 million people at any one time.
A soil-transmitted infection affecting up to 100 million people, particularly children.
A chronic infectious disease which may cause skin lesions and nerve damage found in 127 countries.
Among the most common of all infections with an estimated 1.5 billion people infected worldwide.
Follow our work by signing up for our newsletter
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523
.svg)
